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and indirect (the “cost of illness” analysis), connected with patient treatment at dif-
ferent stage of disease treatment. Epidemiology of ÍÑÑ in Russia was investigated: 
prevalence, incidence, structure of disease depending on age, disease progression, and 
death rate indicators. The expert opinion of real practice of HCC treatment was col-
lected. All these methods allowed to estimate the direct and indirect costs of HCC. 
RESULTS: HCC incidence rate was 2.4 patients per 100,000 population (85% in the 
structure of primary liver cancer). HCC incidence rate index was 8658 patients as of 
2008. In the HCC, structure intermediate stage prevails—61%, the terminal and local 
stages—30% and 9% correspondingly. HCC treatment costs were 2370 bln RUB 
(c67.7 mln) (2008). Direct medical costs were 2208 bln RUB (c63.1 mln) including 
inpatient care (90%), outpatient care (6.6%), and diagnostics (3.4%). Indirect costs 
were 0.161 bln RUB (c4.6 mln) including GDP loses (26%) and payment related with 
temporary disability (74%) The current HCC treatment standards do not correspond 
to international approaches. Very few patients with primary liver cancer get target 
pharmacotherapy. The analysis of actual practice of managing patients with HCC 
shows prevalence of drugs with no indications for usage from the point of view of the 
existing standards and recommendations (form 33% according to regional reimburse-
ment to 58% according to Federal reimbursement). CONCLUSIONS: Developing of 
new standards of HCC treatment including target therapy can reduce the cost of illness 
by reducing off-label use and optimizing the treatment strategy.
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HOSPITAL UNDERTAKING OF PATIENTS WITH A RESECTION OF 
LUNG TUMOR IN FRANCE
Cancalon C, Schmidt A, Bénard S
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OBJECTIVES: With 30,651 new cases diagnosed in 2005, lung cancer is the fourth 
most frequent cancer in France and the ﬁ rst in terms of mortality, with 26,624 deaths 
per year. The survival rate at 5 years is less than 15%. The purpose of this study was 
to describe the 2 years hospital undertaking of patients with a resection of lung tumor 
and to estimate associated hospital costs. METHODS: The 2006 to 2008 PMSI French 
hospital databases were used. Patients with a resection linked to a lung cancer (ICD10 
diagnoses: C33* and C34*) in 2006 were identiﬁ ed and followed up during 2 years. 
Hospital stays, chemotherapy, and radiotherapy sessions were extracted and associ-
ated costs (excluding expensive drugs) were assessed using DRG. Kaplan Meier 
method was applied to estimate associated costs over time, by taking into account 
survival probabilities. RESULTS: In 2006, 8798 patients were hospitalized for a resec-
tion of lung tumor of which 75.8% were men. Mean age at inclusion was 62.4 years; 
2343 patients (26.6%) died in hospital during follow-up. The mean number of hos-
pitalizations for repeated surgery was 0.11 per patient, 2.00 for radiotherapy sessions, 
2.99 for chemotherapy sessions, and 2.57 for other hospitalizations. Total mean 
hospital cost per patient was estimated at c16,169.89 for the 2 years follow-up. First 
surgery account for 48%, repeated surgeries for 6%, radiotherapy session for 2%, 
chemotherapy sessions for 8%, and other hospitalizations for 37%. First month of 
ﬁ rst year supported half of the total cost, and ﬁ rst year bore 86% of it. CONCLU-
SIONS: In France, lung resections for cancer represent a heavy charge for hospitals. 
During the follow-up period, major burden is dedicated to hospital stays especially 
for the ﬁ rst months. These results could be relevant to estimate the impact of coming 
drugs which will be associated to resection of lung tumor.
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OBJECTIVES: Estimating the amount and the structure of annual expenses for treat-
ment of breast cancer (BC) at different stages in Russia. METHODS: Indentifying the 
annual direct costs of treatment BC based on the Russian standard of treatment 
conﬁ rmed by Minister of Health of Russian Federation. Direct costs of BC include 
cost of medical services (MS) (hospitalizations, physician services, diagnosis, surgery, 
and other supporting services), and cost of pharmacotherapy (PT) (cytostatics, hor-
mones and antihormones, accompanying drugs, and other drugs). RESULTS: Annual 
direct costs of treatment BC totaled 138,680, 1,379,980, and 1,923,050 roubles at 
stages I–II, III, IV accordingly. With increase in weight of disease, the relative share 
of expenses for MS decreases and for PT increases. Analyzing the structure of costs 
at different stages showed that the cost of PT is substantial, especially at metastatic 
stage. The presence and relative share of components vary at different stages in struc-
ture of expenses for MS, in which expenses for radiotherapy share about 60% and 
68% at stage III and IV, accordingly. In structure of expenses for PT, the expenses 
for cytostatics are substantial and take 85% at both stages III and IV. Analyzing the 
gain of expenses for separate groups of drugs from stage III to IV showed that expenses 
for cytostatics and accompanying drugs have grown by 43% and 128% accordingly, 
while expenses for other groups have almost not changed. CONCLUSIONS: Expenses 
for treatment BC at different stages vary in size and structure, and rises with increase 
in weight of disease. With the amount of 51,865 patients with BC in 2007 (62.3%, 
26.3%, 10.5% at stages I–II, III, IV accordingly), we received total expenses for treat-
ment of 33,777.217.655 roubles ($1.125.907.255), in which expenses for treatment 
of stage I–II, III, IV are 4.481.031.599 roubles ($149,367,120), 18,823,610,290 
roubles ($627,453,676), and 10,472,593,166 roubles ($349,860,459), accordingly.
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OBJECTIVES: To carry out clinico-economic analysis of treatment of children with 
rhabdomyosarcomas on protocols CWS in Chelyabinsk Region, to estimate medical, 
social, and economic efﬁ ciency of technology. METHODS: We reviewed 21 patients 
<16 years old with rhabdomyosarcomas. All patients received therapy on protocols 
CWS. We used following methods of clinico-economic analysis: cost of illness, cost-
effectiveness analysis, and analysis of the kept years of a life. RESULTS: The sum of 
direct medical expenses for one patient has made US$16,904 dollars, and the total 
sum of direct medical expenses for treatment of 21 patients included in research, has 
made US$354,984. The overall survival rate was 52% that testiﬁ es to high medical 
efﬁ ciency of applied technology. For all groups of patients, the treatment keeps 694.4 
years of a life that makes 33 years of a life on one patient.The parity of a cost/efﬁ ciency 
for one patient has made US$512 dollars for 1 year of the kept life. Considering that 
in 2008 gross national product has made US$9.5 thousand per capita, an expense for 
1 year of the kept life in 18.5 times there is less than parameter of gross national 
product, means that expenses are justiﬁ ed. Before achievement of a pension age, the 
survived patients will work 422 years and will make gross national product for the 
sum US$4009 thousand. The survived patients provide the state with the income 11.2 
times the society for their treatment. CONCLUSIONS: The clinico-economic analysis 
has shown high medical, economic, and social efﬁ ciency of technology of treatment 
of children with rhabdomyosarcomas on protocols CWS.
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OBJECTIVES: To conduct a robust economic evaluation, it is necessary to describe 
current practice and associated costs. Available data on clinical pathways and cost of 
chemotherapy are clinical trial-based, which may not reﬂ ect UK National Health 
Service (NHS) practice. Practice-relevant costs of drug administration, patient moni-
toring and management of adverse events, required for a practice-relevant economic 
model, are not available. This study aimed to inform an economic evaluation by 
describing patient-based cost of NHS patients with advanced colorectal cancer (CRC) 
undergoing irinotecan-based chemotherapy. METHODS: Resource use data were 
collected from the medical records of 48 patients prescribed irinotecan-based (IrMdG) 
chemotherapy at a UK tertiary care center. Using the hospital perspective, data were 
collected from starting chemotherapy until treatment ended. Unit costs were assigned, 
based primarily on NHS Reference Costs 2008/09. Data were analyzed using descrip-
tive statistics and variations around the costs were obtained. Predictors of cost were 
identiﬁ ed from a stepwise multiple regression analysis (ordinary least squares). 
RESULTS: Total cost for 48 patients was £598,765.54 (UK £ 2008/09). Mean cost 
per patient was £12,474.28 (95% CI: £11,233.24–£13,715.32, median £13,307.82, 
range £3,024.48–£21,276.18). Cost components comprised: chemotherapy drugs 
(36.9%), chemotherapy delivery (21.4%), pharmacy cost (15.0%), oncology appoint-
ments (9.5%), central line insertion (5.0%), management of complications and comor-
bidities (5.1%), management of adverse events (4.9%), and imaging (2.2%). Signiﬁ cant 
predictors of increased cost (P < 0.05) identiﬁ ed from the stepwise regression were: 
number of chemotherapy cycles received (adjusted R2 0.81), neutropaenia (adjusted 
R2 0.83), no prior chemotherapy (adjusted R2 0.85), and full-dose chemotherapy 
(adjusted R2 0.86). CONCLUSIONS: This study provides the ﬁ rst data describing 
patient-based costs associated with current NHS practice in this patient group, derived 
from a pragmatic observational study with no trial protocol dictating practice. These 
data should be used in ensuing economic evaluations to ensure relevance to current 
clinical practice.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst, second, third, 
and fourth line of treatment in patients with metastatic colorectal cancer. Costs of 
chemotherapy regimens used as well as supportive care and medical procedures in 
Bulgaria will be estimated (as part of a multinational central European study). 
METHODS: This opinion-based study collected required data by online question-
naire. All information concerning treatment of colorectal cancer was based on experts 
opinion from four oncology centers in Bulgaria. Oncologists had access to medical 
records of approximately 1220 patients treated in year 2008. RESULTS: The leading 
ﬁ rst line regimen (60% of patients) was FOLFOX 4 (oxaliplatin, calcium folinate, and 
ﬂ uorouracil). The most commonly prescribed second-line regimen (50%) was 
FOLFIRI (irinotecan, calcium folinate, and ﬂ uorouracil). Capecitabine was the most 
popular in both the third- (26%) and fourth-line (4%) settings. The percentage of 
patients receiving supportive care increased with disease stage, from 1% in the ﬁ rst, 
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21% in the second, 53% in the third, and 94% in the fourth line. The most common 
treatment algorithm (18%) was FOLFOX, FOLFIRI and supportive care in the ﬁ rst-, 
second-, and third-lines, respectively. Mean regimen costs per patient were estimated 
from a public payer perspective. The most expensive ﬁ rst, second, third and fourth-line 
regimens were FOLFOX 4 (c14,200), FOLFIRI + bevacizumab (c7912c), cetuximab 
+ irinotecan (c7237) and capecitabine (c2609), respectively. CONCLUSIONS: The 
most common regimen in the ﬁ rst line was also the most expensive one. New chemo-
therapeutic agents are associated with improvements in survival time but also with 
substantial costs. Factors inﬂ uencing the selection of chemotherapy included: previous 
therapies, course of the disease, the patient’s performance status, adverse events after 
previous chemotherapies, and concomitant diseases. However, open-ended coverage 
policies for new chemotherapeutic agents may prove difﬁ cult to sustain as costs 
continue to rise.
PCN59
COST OF MANAGEMENT OF BREAST CANCER WITH BRAIN 
METASTASES USING FRENCH HOSPITAL PATIENT CHAINING SYSTEM
Benjamin L1, Cotté FE1, Vainchtock A2, Mercier F3, Vidal-Trécan G4, Durand-Zaleski I5
1GlaxoSmithKline, Health Outcome Studies, Marly le Roi, France; 2HEVA, Lyon, France; 
3StatProcess, Port-Mort, France; 4Hôpital Cochin, Unité de Santé publique, Paris, France; 
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OBJECTIVES: Breast cancer (BC) is the second neoplasm which disseminates brain 
metastases (BM). We estimated the incidence of patients with BCBM, those overex-
pressing HER2 (HER2+), and the costs related to their management using the new 
chaining system of the French hospital information program (PMSI). This was to 
identify predictors of costs. METHODS: A retrospective analysis using the PMSI 
database (2006–2008) was conducted to estimate the number of public and private 
stays related to the diagnosis of BCBM. Stays were extracted and chained to patients’ 
identiﬁ cation number to calculate the number of patients concerned by BCBM. The 
administration of trastuzumab was used as a surrogate for the HER2 status. Costs 
were estimated from the health insurance perspective including health-related group 
tariff, supplements for intensive care, number and length of stays, and expensive-drugs 
status. Spearman’s rank correlation coefﬁ cient and nonparametric test (Kruskal–
Wallis) were used for univariate analyses. RESULTS: In 2008, 3610 women were 
hospitalized for BCBM (vs. 3273 and 3523 in 2006 and 2007, respectively) of whom 
average age was 56.1 years (SD: 13.3). Patients had an average of 4.8 hospitalizations 
(SD: 6.4) mostly for palliative care (42%), chemotherapy (39%), and radiotherapy 
(14%). Twenty-one percent of patients suffered from BM only and 79% had multiple 
metastases; 16% were identiﬁ ed as HER2+. Annual mean cost of care was c8049 per 
patient with BCBM compared with c19,412 speciﬁ cally for HER2+ patients (respec-
tively, 11% and 59% were dedicated to expensive drugs). Age (P < 0.001), patients 
with newly diagnosed BCBM (P < 0.001), and the number of metastases (P < 0.001) 
were associated with the cost of BCBM. CONCLUSIONS: Incidence of BCBM seemed 
to increase during 2006–2008. BCBM management appeared resource-consuming 
especially for HER2+ patients. The development of chaining system in PMSI database 
is an opportunity to estimate economic data accurately as well as to generate epide-
miological data from an exhaustive database.
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CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH 
ADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH EARLY 
STAGE OPERABLE BREAST CANCER
Sail K, Franzini L, Du XL, Lairson D
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OBJECTIVES: Chemotherapy is a major factor contributing to the economic burden 
associated with breast cancer in the elderly. However, there are no clear recommenda-
tions for adjuvant chemotherapy use in elderly women aged 70 and above due to lack 
of efﬁ cacy data in that age group. The study objective was to examine the clinical and 
economic outcomes associated with adjuvant chemotherapy in elderly patients aged 
65 and above with early stage operable breast cancer. METHODS: We studied a 
cohort of 23,110 node positive and 31,572 node negative women aged 65 and over 
diagnosed with incident American Joint Committee on Cancer (AJCC) stage I, II, or 
IIIa breast cancer between January 1, 1991 and December 31, 2002 using SEER-
Medicare data. Total treatment and chemotherapy costs were estimated from the 
Medicare payments using the phase of care approach. Cox proportional hazard ratio 
of mortality was used to determine the effectiveness of adjuvant chemotherapy after 
adjusting for selected patient and tumor characteristics. a propensity score analysis 
was also employed to minimize the bias associated with the receipt of adjuvant che-
motherapy. RESULTS: The difference in the total unadjusted costs for patients who 
received chemotherapy in contrast with patients not receiving any chemotherapy was 
$16,795 in node positive patients and $11,882 in node negative patients. Regression 
adjusted cost estimates for all node positive patients receiving chemotherapy was 
approximately $6500 and was signiﬁ cantly higher (P < 0.05) than for patients not 
receiving chemotherapy. Mortality was signiﬁ cantly reduced in node positive women 
aged 65–69 who received adjuvant chemotherapy compared to those who did not 
receive chemotherapy (HR, 0.66; CI, 0.58–0.74) and in patients aged 70–74 (HR,0.66; 
CI, 0.59–0.74), after adjustment for factors that may affect survival. CONCLUSIONS: 
Decision makers can use cost and effectiveness estimates from this study to assess rela-
tive value of chemotherapy in different age groups.
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COST IMPACT OF ORAL CAPECITABINE COMPARED TO 
5-FLUOROURACIL FOR TREATMENT OF PATIENTS WITH METASTATIC 
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OBJECTIVES: To evaluate the cost of biweekly oxaliplatin plus oral capecitabine 
(OXXEL) versus oxaliplatin combined with leucovorin-modulated 5-ﬂ uorouracil 
(5-FU) given as i.v. bolus every 2 weeks (OXAFAFU) in patients with metastatic 
colorectal cancer (MCRC) in Italy. METHODS: We conducted a multicenter, retro-
spective longitudinal treatment-cost analysis. Direct medical costs attributable to 
MCRC were quantiﬁ ed using 2008 prices and tariffs. The analysis was applied to a 
time horizon of 6 months. The study was conducted from the perspective of the 
National Healthcare Service (NHS). RESULTS: A total of 322 patients (59.9% males; 
mean age 65.2 ± 9.4 years) were analyzed. Mean total cost per patient over follow-up 
period was estimated at c5242.18 ± 2542.06 and c6732.80 ± 3423.72 in the 
Capecitabine and 5-FU arms respectively (P < 0.0001). CONCLUSIONS: The study 
estimated that oral capecitabine administration would produce a saving of c1490.62 
to the NHS. The differences in cost between the two arms are determined by the 
administration route (i.v. vs. oral administration). Therefore, the important economic 
and practical advantage of capecitabine oral home-based therapy is the reduced 
number of hospital visit and the relative costs. Avoiding the hospital access fees 
reduces the impact of higher acquisition cost of capecitabine. Moreover, capecitabine 
in comparison to the 5-FU regimen was associated with lower complication. There-
fore, oral capecitabine may represent a valid alternative in the management of meta-
static colorectal cancer.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, and 
third-line treatment of patients with metastatic colorectal cancer and to estimate costs 
of regimens, supportive care, and medical procedures in Slovakia (part of a multina-
tional study in central Europe). METHODS: In this opinion-based study, data were 
collected by online questionnaire. All information concerning treatment of colorectal 
cancer was based on expert opinion at three oncology centers in Slovakia. Oncologists 
had access to medical records of approximately 1600 patients treated in year 2008. 
RESULTS: The most commonly used ﬁ rst-line regimen (27% of patients) was IFL 
(irinotecan, 5-FU, leucovorin) + bevacizumab. The most commonly prescribed second-
line regimen (27%) was cetuximab + irinotecan and capecitabine was the most 
common third-line regimen (15%). None of patients received supportive care in the 
ﬁ rst line. The percentages of patients receiving supportive care in the second and third 
lines were 27% and 45%, respectively. The most common treatment strategy (8%) 
was ﬁ rst-line capecitabine and supportive care in the second line. Mean regimen costs 
per patient were estimated from a public payer perspective. The most expensive ﬁ rst-
line regimen was IFL + bevacizumab (c36,369). In the second and third lines, modiﬁ ed 
FOLFOX 4 (oxaliplatin, 5-FU, leucovorin) was the most expensive regimen at c31,318 
and c31,572, respectively. CONCLUSIONS: More than 50% of patients received an 
active treatment until the second line. The most common regimen in the ﬁ rst line was 
also the most expensive one. New chemotherapeutic agents are associated with 
improvements in survival time but also with substantial costs. Factors inﬂ uencing the 
selection of chemotherapy included: previous therapies, course of the disease, the 
patient’s performance status, adverse events after previous chemotherapies and con-
comitant diseases. However, open-ended coverage policies for new chemotherapeutic 
agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used and to estimate costs of 
chemotherapy regimens, supportive care, and medical procedures in the ﬁ rst-, second-, 
third-, and fourth-line treatment of patients with metastatic colorectal cancer in Serbia 
(part of a multinational study in central Europe). METHODS: An online questionnaire 
was used to collect necessary information in this opinion-based study. All information 
concerning treatment of colorectal cancer was based on experts opinion from four 
oncology centers in Serbia. Oncologists had access to medical records of approxi-
mately 1760 patients treated in year 2008. RESULTS: The leading ﬁ rst-line regimen 
(38% of patients) was Mayo (Folinic acid, 5-FU). The most commonly prescribed 
second-line regimen (46%%) was FOLFOX 4. Modiﬁ ed FOLFIRI (irinotecan, folinic 
acid, 5-FU) was the most popular regimen in the third line (35%), while FOLFIRI/
cetuximab (35%) was the most commonly used fourth-line regimen. The percentage 
of patients receiving supportive care was 7%, 5%, 10%, and 56% in the ﬁ rst, second, 
third, and fourth lines, respectively. The most common treatment path (8%) was 
FOLFOX 4 B in the ﬁ rst line, FOLFIRI B in the second, and Mitomicin mono in the 
third. Mean regimen costs per patient were estimated from a public payer perspective. 
The most expensive regimen in the ﬁ rst line was bevacizumab + capecitabine + oxali-
